Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply
JAMA Oncol
.
2022 Mar 1;8(3):480.
doi: 10.1001/jamaoncol.2021.6971.
Authors
Kristina Jenei
1
,
Daniel E Meyers
2
,
Vinay Prasad
3
Affiliations
1
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
2
Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
3
Department of Hematology-Oncology, University of California, San Francisco.
PMID:
34989805
DOI:
10.1001/jamaoncol.2021.6971
No abstract available
Publication types
Letter
Comment
MeSH terms
Female
Humans
Medical Oncology*
Neoplasms* / epidemiology
Neoplasms* / therapy
Prevalence